LEADER 03129nam  2200721z- 450 
001 9910557107403321
005 20210501
035   $a(CKB)5400000000040973
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69367
035   $a(oapen)doab69367
035   $a(EXLCZ)995400000000040973
100   $a20202105d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aApheresis in Neurological Disorders
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 online resource (174 p.)
311 08$a3-03943-585-X 
311 08$a3-03943-586-8 
330   $aApheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients' blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain-Barre? syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders.
606   $aMedicine and Nursing$2bicssc
610   $aacute relapsing multiple sclerosis
610   $aAlzheimer's clinical syndrome
610   $aantibody
610   $aapheresis
610   $aautoantibodies
610   $aautoimmune encephalitis
610   $achronic inflammatory demyelinating polyneuropathy
610   $aclass IV
610   $aCRP
610   $adementia
610   $aGuillain-Barre? syndrome
610   $aimmunoadsorption
610   $ainflammation
610   $aInflammatory neuropathy
610   $alimbic encephalitis
610   $amultiple sclerosis
610   $aMyalgic Encephalomyelitis/Chronic Fatigue Syndrome
610   $an/a
610   $aneurological diseases
610   $aNMDAR (N-Methyl-D-Aspartat)
610   $aoptic neuritis
610   $aparaneoplastic
610   $aparanodal antibodies
610   $aplasma exchange
610   $aplasmapheresis
610   $arelapse
610   $aß2 adrenoreceptor autoantibody
610   $asteroids
610   $astroke
610   $atherapeutic apheresis
610   $atherapeutic plasma exchange
610   $a?1-Adrenergic receptor
615  7$aMedicine and Nursing
700   $aDorst$b Johannes$4edt$01294139
702   $aDorst$b Johannes$4oth
906   $aBOOK
912   $a9910557107403321
996   $aApheresis in Neurological Disorders$93022920
997   $aUNINA